GSK escalates mRNA COVID-19 vaccine dispute

The UK pharma giant has opened a new front in its global litigation strategy involving Moderna, Pfizer, and BioNTech.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

$740M deal ends COVID-19 vaccine feud between CureVac and BioNTech

8 August 2025 Payout and licensing deal grants US rights to COVID-19 and flu products | Agreement paves way for BioNTech’s $1.25 billion acquisition of CureVac.

Europe

Pfizer loses UK appeal over Moderna Covid-19 vaccine patent

4 August 2025 UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.

Americas

GSK fires pair of COVID and RSV lawsuits at Moderna

16 October 2024 UK biopharma company says US rival infringed patented mRNA technology I Moderna ‘touted speed’ of Spikevax development but used protected inventions, according to suit | Moderna reported over $6bn globally in 2023 from the Spikevax products.

More features

Trump threatens 100% tariff hike on pharma imports into the US

Budgets, CRISPR, and keeping pace with tech: top challenges for Europe’s patent pros

EU court delivers verdict on Biogen’s market exclusivity for MS drug

Mewburn expands AI and medtech expertise with London hire

AbbVie faces secrets lawsuit over $2.1bn Capstan deal

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

GSK escalates mRNA COVID-19 vaccine dispute

More on this story

Editor's picks

Editor's picks

More features